Evidence map›Paper›PMID 34486186›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2021

Manufacturing of Human Tissues as off-the-Shelf Grafts Programmed to Induce Regeneration.

Sébastien Pigeot, Thibaut Klein, Fabiana Gullotta, Steven J Dupard, Alejandro Garcia Garcia, Andres García-García, Sujeethkumar Prithiviraj, Pilar Lorenzo, Miriam Filippi, Claude Jaquiery and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Review
  2. Development-based In Vivo Bioreactor Strategy for Challenging Senescent Bone Reconstruction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. A Hierarchical Mechanotransduction System: From Macro to Micro.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Sébastien PigeotDepartment of Biomedicine, University Hospital Basel, University of Basel, Basel, 4031, Switzerland.
Thibaut KleinDepartment of Biomedicine, University Hospital Basel, University of Basel, Basel, 4031, Switzerland.
Fabiana GullottaDepartment of Biomedicine, University Hospital Basel, University of Basel, Basel, 4031, Switzerland.
Steven J DupardLaboratory for Cell, Tissue, and Organ Engineering, Department of Clinical Sciences, Lund University, Lund, 221 84, Sweden.
Alejandro Garcia GarciaLaboratory for Cell, Tissue, and Organ Engineering, Department of Clinical Sciences, Lund University, Lund, 221 84, Sweden.
Andres García-GarcíaDepartment of Biomedicine, University Hospital Basel, University of Basel, Basel, 4031, Switzerland.
Sujeethkumar PrithivirajLaboratory for Cell, Tissue, and Organ Engineering, Department of Clinical Sciences, Lund University, Lund, 221 84, Sweden.
Pilar LorenzoWallenberg Center for Molecular Medicine, Lund University, Lund, 221 84, Sweden.
Miriam FilippiDepartment of Biomedicine, University Hospital Basel, University of Basel, Basel, 4031, Switzerland.
Claude JaquieryDepartment of Biomedicine, University Hospital Basel, University of Basel, Basel, 4031, Switzerland.
Loraine KoubaDepartment of Biomedicine, University Hospital Basel, University of Basel, Basel, 4031, Switzerland.
M Adelaide AsnaghiDepartment of Biomedicine, University Hospital Basel, University of Basel, Basel, 4031, Switzerland.
Deepak Bushan RainaDepartment of Clinical Sciences, Orthopedics, Lund University, Lund, 221 84, Sweden.
Boris DasenDepartment of Biomedicine, University Hospital Basel, University of Basel, Basel, 4031, Switzerland.
Hanna IsakssonDepartment of Clinical Sciences, Orthopedics, Lund University, Lund, 221 84, Sweden.
Patrik ÖnnerfjordRheumatology and Molecular Skeletal Biology, Department of Clinical Sciences, Lund University, Lund, 221 84, Sweden.
Magnus TägilDepartment of Clinical Sciences, Orthopedics, Lund University, Lund, 221 84, Sweden.
Attilio BondanzaInnovative Immunotherapies Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Hospital Scientific Institute, Vita-Salute San Raffaele University, Milan, 20132, Italy.
Ivan MartinDepartment of Biomedicine, University Hospital Basel, University of Basel, Basel, 4031, Switzerland.ORCID https://orcid.org/0000-0001-6493-0432
Paul E BourgineDepartment of Biomedicine, University Hospital Basel, University of Basel, Basel, 4031, Switzerland.ORCID https://orcid.org/0000-0002-7639-6844

Funding

Arbeitsgemeinschaft Osteosynthese FoundationDevelopment incubator grantKnut and Alice Wallenberg FoundationMedical Faculty at Lund University and Region SkåneSwedish Research Council 2019-01864Swiss National Science Foundation 310030-133110
6 · The paper itself

Abstract

Design criteria for tissue-engineered materials in regenerative medicine include robust biological effectiveness, off-the-shelf availability, and scalable manufacturing under standardized conditions. For bone repair, existing strategies rely on primary autologous cells, associated with unpredictable performance, limited availability and complex logistic. Here, a conceptual shift based on the manufacturing of devitalized human hypertrophic cartilage (HyC), as cell-free material inducing bone formation by recapitulating the developmental process of endochondral ossification, is reported. The strategy relies on a customized human mesenchymal line expressing bone morphogenetic protein-2 (BMP-2), critically required for robust chondrogenesis and concomitant extracellular matrix (ECM) enrichment. Following apoptosis-driven devitalization, lyophilization, and storage, the resulting off-the-shelf cartilage tissue exhibits unprecedented osteoinductive properties, unmatched by synthetic delivery of BMP-2 or by living engineered grafts. Scalability and pre-clinical efficacy are demonstrated by bioreactor-based production and subsequent orthotopic assessment. The findings exemplify the broader paradigm of programming human cell lines as biological factory units to engineer customized ECMs, designed to activate specific regenerative processes.

Indexed as

Bone Morphogenetic Protein 2Tissue EngineeringAnimalsCartilageCell LineChondrogenesisExtracellular MatrixHumansMesenchymal Stem CellsMiceOsteogenesisRegenerationTissue ScaffoldsBMP2 protein, humanBone Morphogenetic Protein 2BMP2bone graftsendochondral ossificationextracellular matricesregenerative medicine

Identifiers

PMID34486186
PMCPMC11468960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.